<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05111600</url>
  </required_header>
  <id_info>
    <org_study_id>HTA-HG5-02</org_study_id>
    <nct_id>NCT05111600</nct_id>
  </id_info>
  <brief_title>Open-label, Pivotal Clinical Trial to Confirm Efficacy and Safety of Autologous Grafts Containing Stem Cells Genetically Modified for Epidermis Restoration in Patients With Junctional Epidermolysis Bullosa</brief_title>
  <acronym>HOLOGENE 5</acronym>
  <official_title>Multicentre, Open-label, Uncontrolled, Pivotal Clinical Trial to Confirm the Efficacy and Safety of Autologous Fibrin-cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified for Restoration of Epidermis in Patients With Junctional Epidermolysis Bullosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Holostem Terapie Avanzate s.r.l.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Modena and Reggio Emilia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Holostem Terapie Avanzate s.r.l.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter and multinational, open-label, uncontrolled clinical study to assess&#xD;
      the safety and efficacy of autologous cultured epidermal grafts containing epidermal stem&#xD;
      cells genetically modified transduced with a LAMB3-gamma retroviral vector. The purpose of&#xD;
      this study is to demonstrate the safety and efficacy after one or more treatments with&#xD;
      genetically corrected cultured epidermal autograft (Hologene 5) for restoration of the&#xD;
      epidermis in patients with generalized intermediate LAMB3-dependent Junctional Epidermolysis&#xD;
      Bullosa.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial aims to prove the efficacy and safety of RV-LAMB3-transduced epidermal stem cells&#xD;
      and lead to a permanent therapy for the skin lesions affecting JEB patients.&#xD;
&#xD;
      Patients are screened according to the Study Inclusion and Exclusion criteria and if found&#xD;
      eligible, participants are candidate for the treatment. After confirmation of eligibility,&#xD;
      patients will undergo to biopsy for the collection of the autologous epidermal cells used to&#xD;
      produce the tissue for the treatment. If all criteria are met, the transplantation of the new&#xD;
      cultured transgenic epidermis will be planned according to the procedures and the need of the&#xD;
      patient. The study treatment consists of a surgical intervention for new restored stem cells&#xD;
      implantation. The surgery is carried out in 2 stages, the first aims at taking biopsy to&#xD;
      isolate epidermal cells including stem cells. The biopsy is processed in a laboratory of a&#xD;
      regenerative medicine manufacturing site where the tissue is corrected, expanded and prepared&#xD;
      as final sheets to be implanted. Afterward, the patient undergoes to the second intervention&#xD;
      when the grafts containing genetically corrected cultured keratinocytes (Hologene-5) are&#xD;
      implanted into the selected area under local or general anaesthesia.&#xD;
&#xD;
      The treated area is then immobilized for some days after this surgery. Antibiotics and&#xD;
      anti-inflammatory drugs may be administered (if necessary) to prevent infections and to&#xD;
      minimise swelling.&#xD;
&#xD;
      The follow-up after implantation is 12 months. The treatment can be repeated. The end of the&#xD;
      trial is defined as the last visit of the last patient after the last treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Re-epithelialization</measure>
    <time_frame>12 months</time_frame>
    <description>Re-epithelialization in absence of blisters in at least 50% of the transplanted area measured by the Investigator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Protein residual expression</measure>
    <time_frame>12 months</time_frame>
    <description>Protein residual expression resulting in 'Yes' or 'Partial' measured by Immunofluorescence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expression of transgenic mRNA</measure>
    <time_frame>12 months</time_frame>
    <description>Expression of transgenic mRNA resulting in 'Yes' or 'Partial' measured by In situ hybridization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemidesmosomes presence</measure>
    <time_frame>12 months</time_frame>
    <description>Presence of hemidesmosomes measured by electron microscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin stability</measure>
    <time_frame>12 months</time_frame>
    <description>Negativity or positivity at the stripping test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Outcome</measure>
    <time_frame>12 months</time_frame>
    <description>Chnage in Patient Reported Outcome score measured by 5-points Likert scale, where: 1=Definitely Worsened, 2=Slightly Worsened, 3=Unchanged, 4=Slightly Improved, 5=Definitely Improved</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Re-epithelialization by Independent Assessor</measure>
    <time_frame>12 months</time_frame>
    <description>% of re-epithelialization assessed by the Independent Assessor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life improvement</measure>
    <time_frame>12 months</time_frame>
    <description>Change in EBDASI (Epidermolysis Bullosa Disease Activity and Scarring Index) skin section score, where Best score=0 and Worse score=120 for Activity and Best score=0 and Worse score=84 for Damage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Number and % of treatment-emergent adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Number and % of serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events of special interest</measure>
    <time_frame>12 months</time_frame>
    <description>Number and % of adverse events of special interest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug reactions</measure>
    <time_frame>12 months</time_frame>
    <description>Number and % of adverse drug reactions</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Junctional Epidermolysis Bullosa Non-Herlitz Type</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After confirmation of eligibility criteria and ICF signature, subject undergoes to skin biopsy for collection of autologous epidermal cells to be used to produce IMP under GMP process. Approximately 2 months later, IMP is transplanted on selected area.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transplantation</intervention_name>
    <description>Implantation of autologous cultured grafts containing genetically modified stem cells for restoration of functional skin on pre-selected areas</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Engraftment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated informed consent prior to any study-related procedures.&#xD;
&#xD;
          2. Male and female patients between 6 months and 65 years old;&#xD;
&#xD;
          3. Diagnosis of generalized intermediate LAMB3-dependent JEB, confirmed by NGS or Sanger&#xD;
             sequencing and/or immunofluorescence;&#xD;
&#xD;
          4. Detectable residual expression of laminin 332 (and its beta-3 chain) by&#xD;
             immunofluorescence and/or Western Blot analysis;&#xD;
&#xD;
          5. Presence of blisters and/or ≥ 6 cm2 erosions (persistent or recurrent for more than 3&#xD;
             months); the area of the erosion can be considered as the sum of smaller areas in the&#xD;
             same body part (i.e. leg, thigh, arm, …)&#xD;
&#xD;
          6. A cooperative attitude to follow the study procedures (caregivers in case of&#xD;
             children);&#xD;
&#xD;
          7. Patients' compliance with the study schedule and procedures, including complete&#xD;
             immobilization of the transplanted areas for at least two weeks and hospitalization up&#xD;
             to 1 month after transplantation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known or suspected intolerance to anaesthesia;&#xD;
&#xD;
          2. Bad general condition (ECOG index &gt;1);&#xD;
&#xD;
          3. Presence of any skin cancers in the area(s) qualified for treatment;&#xD;
&#xD;
          4. Clinical and/or laboratory signs of acute systemic infections at the time of&#xD;
             screening. Patient can be re-screened after appropriate treatment;&#xD;
&#xD;
          5. Female subjects: Pregnant (as evident by a positive urine hCG or serum-hCG test) or&#xD;
             lactating women and all women physiologically capable of becoming pregnant (i.e. women&#xD;
             of childbearing potential [WOCBP]) UNLESS they are willing to use highly effective&#xD;
             birth control methods;&#xD;
&#xD;
          6. Allergy, sensitivity or intolerance to study medication excipients or other material&#xD;
             required by study protocol (as per Investigator's brochure)&#xD;
&#xD;
          7. Contraindications to the local or systemic antibiotics and/or corticosteroids foreseen&#xD;
             by the protocol;&#xD;
&#xD;
          8. Contraindications to undergo extensive surgical procedures;&#xD;
&#xD;
          9. Presence of i) systemic diseases, ii) clinically significant or unstable concurrent&#xD;
             disease, iii) other concomitant medical conditions, iv) other clinical&#xD;
             contraindications to stem cell transplantation, which based on Investigator's&#xD;
             judgment, in consultation with the Sponsor Medical Expert may affect the participation&#xD;
             in the study or the grafting procedure;&#xD;
&#xD;
         10. Patients (or parents in case of paediatric subject) unlikely to comply with the study&#xD;
             protocol or unable to understand the nature and scope of the study or the possible&#xD;
             benefits or unwanted effects of the study procedures and treatments.&#xD;
&#xD;
         11. Previous treatments or clinical trials envisaging the use of cells (including bone&#xD;
             marrow transplantation, BMT) and/or both in vivo or ex vivo gene therapy products.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristina Magnoni, MD, Surgeon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Struttura Complessa di Dermatologia Azienda Ospedaliero Universitaria Policlinico di Modena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Info Holostem Terapie Avanzate Srl</last_name>
    <phone>+39 059 2058070</phone>
    <email>ClinicalTrials-info@holostem.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michele De Luca, MD</last_name>
    <email>m.deluca@holostem.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Christine Bodemer, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christine Bodemer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen Kinder- und Jugendklinik</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Holm Schneider, MD</last_name>
    </contact>
    <investigator>
      <last_name>Holm Schneider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa di Dermatologia Azienda Ospedaliero Universitaria Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Cristina Magnoni, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cristina Magnoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://links.email.frontiersin.org/ls/click?upn=Dpg5ochww630xh6EMvshS4k2vZe-2Fd8MH-2FVpzt1-2FUQD91C-2FNL5bIclwWnNjv5HD9izZCaOx2V3EtqIs0Ckedw-2F1A-2BcH3PXDfrM3tKsGvB5mOBFA4D4IQsXZBBoywIR8CqP788TC4QjwkjLexp8GkbdobTlDoKSXKIZ4hzFDGy-2BSoPWinVxRUD26SZk4zWlZmIujIlA-2FcuhGtrzCic2TjA6R9WgboLuof6h4bANVfct1-2BR0PaKBaVQpkvKuBSjOwJY97llGsKrkBbQeTFucCWc6XjFbhLpgcO4VwoW0SZPxFOMb0wxr9TxMiyhhXdL-2Fj3ryc_c_Uho53-2BBXHz3IQwFuqmgP8k0vc6XETh9Rxa541lPSMSnGAcDSIwNa63R8LWkU68mnnscH3GsPwiS7GYOTbVFnuLvR-2F6xG6nfgMBA6u57DAAcghHjoQgF1ekrer-2BMmuEgMoSQJ-2Br7xcgVDOTCTOisKEFWCQ14VP684FGXCk8kzV87l0diRwtDJAzg4RRyX46iK-2F7fkoeyDaTJnM3mYt5-2BqgmH9nN2J575hO0RVIJvYWZCkku-2Fsh7f63TYQ3gN2rLlX</url>
    <description>Hologene 5: A Phase II/III Clinical Trial of Combined Cell and Gene Therapy of Junctional Epidermolysis Bullosa</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 1, 2021</study_first_submitted>
  <study_first_submitted_qc>October 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidermolysis Bullosa</mesh_term>
    <mesh_term>Epidermolysis Bullosa, Junctional</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

